uniQure N.V. (NASDAQ:QURE) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• uniQure N.V. has received a consensus rating of "Moderate Buy" from twelve analysts, with an average 12-month price target of $71.75.
• Recent insider transactions showed significant sales of shares by both CFO Christian Klemt and CEO Matthew C. Kapusta, with the former selling 15,000 shares and the latter selling 226,316 shares.
• Multiple institutional investors have increased their stakes in uniQure, highlighting strong interest and confidence in the company, with hedge funds owning 78.83% of the stock.

Shares of uniQure N.V. (NASDAQ:QURE - Get Free Report) have received an average recommendation of "Moderate Buy" from the twelve analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, nine have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $71.75.

Several equities research analysts have recently commented on the stock. Cantor Fitzgerald boosted their price target on shares of uniQure from $47.00 to $80.00 and gave the company an "overweight" rating in a report on Thursday, September 25th. Guggenheim boosted their price target on shares of uniQure from $28.00 to $95.00 and gave the company a "buy" rating in a report on Thursday, September 25th. Chardan Capital boosted their price target on shares of uniQure from $35.00 to $76.00 and gave the company a "buy" rating in a report on Thursday, September 25th. Royal Bank Of Canada restated an "outperform" rating on shares of uniQure in a report on Wednesday, September 24th. Finally, Wall Street Zen upgraded shares of uniQure from a "sell" rating to a "hold" rating in a report on Saturday, August 2nd.

Insider Buying and Selling

In other news, CFO Christian Klemt sold 15,000 shares of uniQure stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $55.00, for a total value of $825,000.00. Following the transaction, the chief financial officer owned 217,730 shares of the company's stock, valued at $11,975,150. The trade was a 6.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Matthew C. Kapusta sold 226,316 shares of uniQure stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total transaction of $9,383,061.36. Following the completion of the transaction, the chief executive officer directly owned 651,454 shares in the company, valued at approximately $27,009,282.84. The trade was a 25.78% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 244,316 shares of company stock worth $10,328,181. Insiders own 4.79% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Voya Investment Management LLC grew its position in shares of uniQure by 51.8% in the 3rd quarter. Voya Investment Management LLC now owns 102,124 shares of the biotechnology company's stock worth $5,961,000 after buying an additional 34,864 shares during the last quarter. Sanders Morris Harris LLC acquired a new position in uniQure during the 3rd quarter valued at approximately $5,081,000. Headlands Technologies LLC increased its stake in uniQure by 304.4% during the 2nd quarter. Headlands Technologies LLC now owns 42,444 shares of the biotechnology company's stock valued at $592,000 after purchasing an additional 31,948 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in uniQure by 358.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 5,538 shares in the last quarter. Finally, Corient Private Wealth LLC increased its stake in uniQure by 100.0% during the 2nd quarter. Corient Private Wealth LLC now owns 21,260 shares of the biotechnology company's stock valued at $296,000 after purchasing an additional 10,630 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company's stock.

uniQure Trading Down 3.3%

Shares of QURE opened at $61.56 on Friday. uniQure has a 1-year low of $5.23 and a 1-year high of $65.12. The company has a 50-day moving average of $26.10 and a 200 day moving average of $17.92. The firm has a market capitalization of $3.38 billion, a price-to-earnings ratio of -15.70 and a beta of 0.56. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98.

uniQure (NASDAQ:QURE - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share for the quarter, beating analysts' consensus estimates of ($0.89) by $0.20. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The company had revenue of $5.26 million during the quarter, compared to analyst estimates of $5.00 million. On average, research analysts expect that uniQure will post -3.75 EPS for the current year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.